Haider Mahdi

Jan 16, 2025 | biorxiv.org | Lin Li |Lamis Yehia |Haider Mahdi |Gideon Idumah

AbstractModifiers of immune checkpoint inhibitor (ICI) responses in cancer patients are complex and remain poorly characterized, especially in gynecologic cancers. In this study, we explored fluxomic biomarkers that differentiate responders from non-responders to ICIs in a series of 49 patients with gynecologic cancers, including ovarian, cervical, and endometrial cancers.